Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 15/20 | 0.60 |
| ▸ | NAALAD2 | Q9Y3Q0 | 5/20 | 0.55 |
| ▸ | MME | P08473 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11930754 | 0.90 | FOLH1 (0.74) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL1740438 | 0.75 | FOLH1 (1.00) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL4139164 | 0.75 | FOLH1 (1.00) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL24489505 | 0.75 | KDM6B (0.47) | FOLH1MMEACE | |
| SCHEMBL1828830 | 0.74 | ESR1 (0.49) | FOLH1MMEACE | |
| SCHEMBL1828829 | 0.74 | ESR1 (0.49) | FOLH1MMEACE | |
| SCHEMBL11977627 | 0.73 | NAALAD2 (0.77) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL23314718 | 0.72 | FOLH1 (0.50) | FOLH1MMEACE | |
| SCHEMBL9965331 | 0.72 | NAALAD2 (1.00) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL13515316 | 0.72 | NAALAD2 (1.00) | FOLH1NAALAD2RIMKLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647666-B2 | Heterodimers of glutamic acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20190276393-A1 | Heterodimers of Glutamic Acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2019-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190276393-A1 | Heterodimers of Glutamic Acid | GLUL, DDO, ASNS | FOLH1 4/4885NAALAD2 16/4885MME 1336/4885 |
| US-10647666-B2 | Heterodimers of glutamic acid | DDO, GLUL, ASNS | FOLH1 5/4885NAALAD2 7/4885MME 1896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.